| Species |
Human |
| Protein Construction |
OX40/TNFRSF4/CD134 (Leu29-Ala216)_x000D_
Accession # P43489 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human OX40 Ligand Trimer, His Tag at 1μg/ml (100μl/well) on the plate can bind OX40/TNFRSF4/CD134 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
46.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-78 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. |
| Synonyms |
CD134; OX40; OX40L receptor; TNFRSF4; ACT-135; Ly-70; OX40 homologue; TXGP1L; IMD16 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
